Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial

Post time 2024-4-27 05:41:29

journal：Diabetes, Obesity and Metabolism

Authors：Akihiko Koshino; Megumi Oshima; Clare Arnott; Robert A. Fletcher; George L. Bakris; Meg Jardine; Kenneth W. Mahaffey; Vlado Perkovic; Carol Pollock; Hiddo J. L. Heerspink; Brendon L. Neuen

Published date：2023-5-

DOI：10.1111/dom.14978

PDF link：https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.14978

Article link：http://dx.doi.org/10.1111/dom.14978

Article Source：Wiley。

Remark：PLEASE HELP ME

Post time 2024-4-27 05:41:30

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Wiley] Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial